BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16585812)

  • 1. Anti-diabetic drug use and the risk of motor vehicle crash in the elderly.
    Hemmelgarn B; Lévesque LE; Suissa S
    Can J Clin Pharmacol; 2006; 13(1):e112-20. PubMed ID: 16585812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
    Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes.
    Johnson JA; Simpson SH; Toth EL; Majumdar SR
    Diabet Med; 2005 Apr; 22(4):497-502. PubMed ID: 15787679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.
    Azoulay L; Schneider-Lindner V; Dell'aniello S; Schiffrin A; Suissa S
    Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):335-42. PubMed ID: 20052677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
    Gulliford M; Latinovic R
    Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis.
    Bodmer M; Becker C; Meier C; Jick SS; Meier CR
    Am J Gastroenterol; 2012 Apr; 107(4):620-6. PubMed ID: 22290402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents.
    Koro C; Barrett S; Qizilbash N
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):485-92. PubMed ID: 17192841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychoactive substance use and the risk of motor vehicle accidents.
    Movig KL; Mathijssen MP; Nagel PH; van Egmond T; de Gier JJ; Leufkens HG; Egberts AC
    Accid Anal Prev; 2004 Jul; 36(4):631-6. PubMed ID: 15094417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzodiazepine use and the risk of motor vehicle crash in the elderly.
    Hemmelgarn B; Suissa S; Huang A; Boivin JF; Pinard G
    JAMA; 1997 Jul; 278(1):27-31. PubMed ID: 9207334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
    Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
    CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
    Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
    Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation).
    Kogut SJ; Andrade SE; Willey C; Larrat EP
    Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):591-8. PubMed ID: 15362081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
    Kahler KH; Rajan M; Rhoads GG; Safford MM; Demissie K; Lu SE; Pogach LM
    Diabetes Care; 2007 Jul; 30(7):1689-93. PubMed ID: 17440170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea.
    Becker ML; Aarnoudse AJ; Newton-Cheh C; Hofman A; Witteman JC; Uitterlinden AG; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2008 Jul; 18(7):591-7. PubMed ID: 18551039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin use and the risk of motor vehicle crash in older drivers.
    Delaney JA; Opatrny L; Suissa S
    Br J Clin Pharmacol; 2006 Feb; 61(2):229-32. PubMed ID: 16433878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.
    Johnson JA; Majumdar SR; Simpson SH; Toth EL
    Diabetes Care; 2002 Dec; 25(12):2244-8. PubMed ID: 12453968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.